Literature DB >> 16254213

Impaired CXCR4 signaling contributes to the reduced neovascularization capacity of endothelial progenitor cells from patients with coronary artery disease.

Dirk H Walter1, Judith Haendeler, Johannes Reinhold, Ulrich Rochwalsky, Florian Seeger, Jörg Honold, Jörg Hoffmann, Carmen Urbich, Ralf Lehmann, Fernando Arenzana-Seisdesdos, Alexandra Aicher, Christopher Heeschen, Stephan Fichtlscherer, Andreas M Zeiher, Stefanie Dimmeler.   

Abstract

Transplantation of bone marrow cells as well as circulating endothelial progenitor cells (EPC) enhances neovascularization after ischemia. The chemokine receptor CXCR4 is essential for migration and homing of hematopoietic stem cells. Therefore, we investigated the role of CXCR4 and its downstream signaling cascade for the angiogenic capacity of cultured human EPC. Ex vivo, differentiated EPC derived from peripheral blood abundantly expressed CXCR4. Incubation of EPC from healthy volunteers with neutralizing antibodies against CXCR4 profoundly inhibited vascular endothelial growth factor- and stromal-derived factor-1-induced migration as well as EPC-induced angiogenesis in an ex vivo assay. Preincubation of transplanted EPC with CXCR4 antibody reduced EPC incorporation and impaired blood-flow recovery in ischemic hindlimbs of nude mice (57+/-4% of normal perfusion versus untreated EPC: 80+/-11%, P<0.001). Bone marrow mononuclear cells (BM-MNC) or EPC of heterozygous CXCR4(+/-) mice displayed reduced CXCR4 expression and disclosed impaired in vivo capacity to enhance recovery of ischemic blood flow in nude mice (blood flow 27+/-11% versus 66+/-25% using wild-type cells, P<0.01). Importantly, impaired blood flow in ischemic CXCR4(+/-) mice was rescued by injection of wild-type BM-MNC. Next, we investigated the role of CXCR4 for functional capacities of EPC from patients with coronary artery disease (CAD). Surface expression of CXCR4 was similar in EPC from patients with CAD compared with healthy controls. However, basal Janus kinase (JAK)-2 phosphorylation was significantly reduced and less responsive to stromal-derived factor-1 in EPC from patients with CAD compared with healthy volunteers, indicating that CXCR4-mediated JAK-2 signaling is dysregulated in EPC from patients with CAD. The CXCR4 receptor signaling profoundly modulates the angiogenic activity and homing capacity of cultured human EPC. Disturbance of CXCR4 signaling, as demonstrated by reduced JAK-2 phosphorylation, may contribute to functional impairment of EPC from patients with CAD. Stimulating CXCR4 signaling might improve functional properties of EPC and may rescue impaired neovascularization capacity of EPC derived from patients with CAD.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16254213     DOI: 10.1161/01.RES.0000193596.94936.2c

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  105 in total

1.  Identification and characterization of a resident vascular stem/progenitor cell population in preexisting blood vessels.

Authors:  Hisamichi Naito; Hiroyasu Kidoya; Susumu Sakimoto; Taku Wakabayashi; Nobuyuki Takakura
Journal:  EMBO J       Date:  2011-12-16       Impact factor: 11.598

2.  Maintenance and repair of the lung endothelium does not involve contributions from marrow-derived endothelial precursor cells.

Authors:  Sarah J Ohle; Asha Anandaiah; Attila J Fabian; Alan Fine; Darrell N Kotton
Journal:  Am J Respir Cell Mol Biol       Date:  2012-02-09       Impact factor: 6.914

3.  Intramuscular VEGF activates an SDF1-dependent progenitor cell cascade and an SDF1-independent muscle paracrine cascade for cardiac repair.

Authors:  David Zisa; Arsalan Shabbir; Michalis Mastri; Tyler Taylor; Ilija Aleksic; Mary McDaniel; Gen Suzuki; Techung Lee
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-09-30       Impact factor: 4.733

Review 4.  Cardiac stem cell therapy and arrhythmogenicity: prometheus and the arrows of Apollo and Artemis.

Authors:  Alexander R Lyon; Sian E Harding; Nicholas S Peters
Journal:  J Cardiovasc Transl Res       Date:  2008-07-16       Impact factor: 4.132

5.  Endothelial progenitor cells=EPC=elemental pernicious complexity.

Authors:  Ralf P Brandes; Masuko Ushio-Fukai
Journal:  Antioxid Redox Signal       Date:  2011-04-26       Impact factor: 8.401

6.  Improved mobilization of the CD34(+) and CD133(+) bone marrow-derived circulating progenitor cells by freshly isolated intracoronary bone marrow cell transplantation in patients with ischemic heart disease.

Authors:  Ramazan Gökmen Turan; Ilkay Bozdag-Turan; Jasmin Ortak; Ibrahim Akin; Stephan Kische; Henrik Schneider; Cem Hakan Turan; Tim Christopher Rehders; Mathias Rauchhaus; Tilo Kleinfeldt; Ester Adolph; Micheal Brehm; Sedat Yokus; Stephan Steiner; Kurtulus Sahin; Christoph A Nienaber; Hüseyin Ince
Journal:  Stem Cells Dev       Date:  2010-12-29       Impact factor: 3.272

7.  The E3 ubiquitin ligase atrophin interacting protein 4 binds directly to the chemokine receptor CXCR4 via a novel WW domain-mediated interaction.

Authors:  Deepali Bhandari; Seth L Robia; Adriano Marchese
Journal:  Mol Biol Cell       Date:  2008-12-30       Impact factor: 4.138

8.  Effects of AMD3100 subconjunctival injection on alkali burn induced corneal neovascularization in mice.

Authors:  Liang-Hong Peng; Wei Shen; Wang Yong; Lu Lu; Lin Liu
Journal:  Int J Ophthalmol       Date:  2011-02-18       Impact factor: 1.779

9.  Human vascular progenitor cells derived from renal arteries are endothelial-like and assist in the repair of injured renal capillary networks.

Authors:  Paul Pang; Molly Abbott; Steven L Chang; Malyun Abdi; Nikita Chauhan; Murti Mistri; Joshua Ghofrani; Quynh-Anh Fucci; Colleen Walker; Corey Leonardi; Samuel Grady; Arvin Halim; Ryan Hoffman; Tzongshi Lu; Huixia Cao; Stefan G Tullius; Sayeed Malek; Sanjaya Kumar; Graeme Steele; Adam Kibel; Benjamin S Freedman; Sushrut S Waikar; Andrew M Siedlecki
Journal:  Kidney Int       Date:  2016-09-29       Impact factor: 10.612

10.  Regenerative cell therapy and pharmacotherapeutic intervention in heart failure: Part 2: Pharmacological targets, agents and intervention perspectives.

Authors:  C Qian; R G Schoemaker; W H van Gilst; B Yu; A J M Roks
Journal:  Neth Heart J       Date:  2008-10       Impact factor: 2.380

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.